222 related articles for article (PubMed ID: 38289577)
1. Increased Cardiovascular Risk in Young Patients with CKD and the Role of Lipid-Lowering Therapy.
Kratky V; Valerianova A; Hruskova Z; Tesar V; Malik J
Curr Atheroscler Rep; 2024 Apr; 26(4):103-109. PubMed ID: 38289577
[TBL] [Abstract][Full Text] [Related]
2. Lipid-lowering agents for concurrent cardiovascular and chronic kidney disease.
Katsiki N; Mikhailidis DP; Banach M
Expert Opin Pharmacother; 2019 Nov; 20(16):2007-2017. PubMed ID: 31344332
[No Abstract] [Full Text] [Related]
3. Lipid Management in Chronic Kidney Disease: Systematic Review of PCSK9 Targeting.
Zheng-Lin B; Ortiz A
Drugs; 2018 Feb; 78(2):215-229. PubMed ID: 29299849
[TBL] [Abstract][Full Text] [Related]
4. Managing dyslipidaemia in patients with chronic kidney disease.
Mehta A
Indian Heart J; 2024 Mar; 76 Suppl 1(Suppl 1):S90-S92. PubMed ID: 38278323
[TBL] [Abstract][Full Text] [Related]
5. PCSK9 inhibitors and ezetimibe for the reduction of cardiovascular events: a clinical practice guideline with risk-stratified recommendations.
Hao Q; Aertgeerts B; Guyatt G; Bekkering GE; Vandvik PO; Khan SU; Rodondi N; Jackson R; Reny JL; Al Ansary L; Van Driel M; Assendelft WJJ; Agoritsas T; Spencer F; Siemieniuk RAC; Lytvyn L; Heen AF; Zhao Q; Riaz IB; Ramaekers D; Okwen PM; Zhu Y; Dawson A; Ovidiu MC; Vanbrabant W; Li S; Delvaux N
BMJ; 2022 May; 377():e069066. PubMed ID: 35508320
[TBL] [Abstract][Full Text] [Related]
6. LDL-cholesterol lowering and renal outcomes.
Waters DD
Curr Opin Lipidol; 2015 Jun; 26(3):195-9. PubMed ID: 25887677
[TBL] [Abstract][Full Text] [Related]
7. Proprotein convertase subtilisin/kexin type 9 in kidney disease.
Schmit D; Fliser D; Speer T
Nephrol Dial Transplant; 2019 Aug; 34(8):1266-1271. PubMed ID: 31190079
[TBL] [Abstract][Full Text] [Related]
8. Management of Hypercholesterolemia, Appropriateness of Therapeutic Approaches and New Drugs in Patients with High Cardiovascular Risk.
Agabiti Rosei E; Salvetti M
High Blood Press Cardiovasc Prev; 2016 Sep; 23(3):217-30. PubMed ID: 27567901
[TBL] [Abstract][Full Text] [Related]
9. Use of lipid-lowering therapies in patients with chronic kidney disease and atherosclerotic cardiovascular disease: 2-year results from Getting to an imprOved Understanding of Low-Density lipoprotein cholesterol and dyslipidemia management (GOULD).
Shaik A; Kosiborod M; de Lemos JA; Gao Q; Mues KE; Alam S; Bhatt DL; Cannon CP; Ballantyne CM; Rosenson RS;
Clin Cardiol; 2022 Dec; 45(12):1303-1310. PubMed ID: 36124341
[TBL] [Abstract][Full Text] [Related]
10. 2017 Taiwan lipid guidelines for high risk patients.
Li YH; Ueng KC; Jeng JS; Charng MJ; Lin TH; Chien KL; Wang CY; Chao TH; Liu PY; Su CH; Chien SC; Liou CW; Tang SC; Lee CC; Yu TY; Chen JW; Wu CC; Yeh HI;
J Formos Med Assoc; 2017 Apr; 116(4):217-248. PubMed ID: 28242176
[TBL] [Abstract][Full Text] [Related]
11. Novel aspects of PCSK9 and lipoprotein receptors in renal disease-related dyslipidemia.
Shrestha P; van de Sluis B; Dullaart RPF; van den Born J
Cell Signal; 2019 Mar; 55():53-64. PubMed ID: 30550765
[TBL] [Abstract][Full Text] [Related]
12. LDL-cholesterol reduction in chronic kidney disease: options beyond statins.
Goonasekera MA; Mafham MM; Haynes RJ
Curr Opin Nephrol Hypertens; 2020 Sep; 29(5):480-488. PubMed ID: 32701596
[TBL] [Abstract][Full Text] [Related]
13. New LDL-cholesterol lowering therapies: pharmacology, clinical trials, and relevance to acute coronary syndromes.
Sahebkar A; Watts GF
Clin Ther; 2013 Aug; 35(8):1082-98. PubMed ID: 23932550
[TBL] [Abstract][Full Text] [Related]
14. Ezetimibe for the prevention of cardiovascular disease and all-cause mortality events.
Zhan S; Tang M; Liu F; Xia P; Shu M; Wu X
Cochrane Database Syst Rev; 2018 Nov; 11(11):CD012502. PubMed ID: 30480766
[TBL] [Abstract][Full Text] [Related]
15. [Hypercholesterolemia and cardiovascular risk].
Sinning D; Landmesser U
Dtsch Med Wochenschr; 2023 Aug; 148(16):1025-1032. PubMed ID: 37541292
[TBL] [Abstract][Full Text] [Related]
16. Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibition and the Future of Lipid Lowering Therapy.
Joseph L; Robinson JG
Prog Cardiovasc Dis; 2015; 58(1):19-31. PubMed ID: 25936907
[TBL] [Abstract][Full Text] [Related]
17. Association of a Combined Measure of Adherence and Treatment Intensity With Cardiovascular Outcomes in Patients With Atherosclerosis or Other Cardiovascular Risk Factors Treated With Statins and/or Ezetimibe.
Khunti K; Danese MD; Kutikova L; Catterick D; Sorio-Vilela F; Gleeson M; Kondapally Seshasai SR; Brownrigg J; Ray KK
JAMA Netw Open; 2018 Dec; 1(8):e185554. PubMed ID: 30646277
[TBL] [Abstract][Full Text] [Related]
18. Endothelin Receptor Antagonism Improves Lipid Profiles and Lowers PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) in Patients With Chronic Kidney Disease.
Farrah TE; Anand A; Gallacher PJ; Kimmitt R; Carter E; Dear JW; Mills NL; Webb DJ; Dhaun N
Hypertension; 2019 Aug; 74(2):323-330. PubMed ID: 31177906
[TBL] [Abstract][Full Text] [Related]
19. A reappraisal of the risks and benefits of treating to target with cholesterol lowering drugs.
Alla VM; Agrawal V; DeNazareth A; Mohiuddin S; Ravilla S; Rendell M
Drugs; 2013 Jul; 73(10):1025-54. PubMed ID: 23754124
[TBL] [Abstract][Full Text] [Related]
20. PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease.
Schmidt AF; Carter JL; Pearce LS; Wilkins JT; Overington JP; Hingorani AD; Casas JP
Cochrane Database Syst Rev; 2020 Oct; 10(10):CD011748. PubMed ID: 33078867
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
